Published online before print February 16, 2004, doi: 10.1161/01.HYP.0000120125.08867.42
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2004;43:791.)
© 2004 American Heart Association, Inc.
Scientific Contributions |
C-Reactive Protein Modifies the Relationship Between Blood Pressure and Microalbuminuria
From the Department of Medicine (E.M.S., S.J.L.B., R.O.B.G.), Trial Coordination Center (H.L.H.), Department of Epidemiology & Statistics (J.G.M.B.), Department of Nephrology (P.E.d.J.), Department of Medicine, Department of Clinical Pharmacology (D.d.Z.), University Medical Center, Groningen, The Netherlands.
Correspondence to Dr D. de Zeeuw, Professor and Head, Department of Clinical Pharmacology, University Medical Center, Ant. Deusinglaan 1, 9713 AV, PO Box 196, Groningen, The Netherlands. E-mail d.de.zeeuw{at}med.rug.nl
C-reactive protein (CRP) and microalbuminuria reflect intimately related components of the atherosclerotic disease process. Epidemiological studies found only modest associations between CRP and microalbuminuria. Blood pressure, one of the components of the metabolic syndrome in the general population, is the main determinant of microalbuminuria in diabetes and hypertension. We questioned whether CRP modifies the relationship of blood pressure and other cardiovascular risk factors with microalbuminuria in a cross-sectional study in 8592 inhabitants from Groningen, The Netherlands. The crude data showed an increase in the prevalence of microalbuminuria with increasing CRP quartiles (4.8, 9.6, 14.5, and 18.6%, P<0.0001). On stratification for cardiovascular risk factors, the data revealed a significant and positive interaction between mean arterial pressure (MAP) and quartiles of CRP with respect to the risk of microalbuminuria (Wald statistic 9.2, P=0.03). In subjects with a MAP <90 mm Hg, a nonsignificant trend in the association between CRP quartiles and microalbuminuria was found (prevalence: 3.9%, 5.8%, 6.6%, 8.7%; P=0.11). This trend was much steeper and significant in subjects with an MAP >90 mm Hg (prevalence: 6.7%, 13.6%, 20.4%, 25.1%; P<0.0001). Controlling for other risk factors in multivariate analyses, the positive interaction persisted (P=0.0004). No significant interactions between other risk factors and CRP with respect to the risk of microalbuminuria were encountered. Thus, CRP modifies the relation between blood pressure and microalbuminuria.
Key Words: cardiovascular diseases • blood pressure • risk factors • kidney • albuminuria
This article has been cited by other articles:
 |
|
 |
|
  A. Mimran and G. du Cailar Dietary sodium: the dark horse amongst cardiovascular and renal risk factors Nephrol. Dial. Transplant., July 1, 2008; 23(7): 2138 - 2141. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Danziger Importance of Low-Grade Albuminuria Mayo Clin. Proc., July 1, 2008; 83(7): 806 - 812. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Basi, P. Fesler, A. Mimran, and J. B. Lewis Microalbuminuria in Type 2 Diabetes and Hypertension: A marker, treatment target, or innocent bystander? Diabetes Care, February 1, 2008; 31(Supplement_2): S194 - S201. [Full Text] [PDF]
|
|
|
|
 |
|
 G. F. Salles, R. Fiszman, C. R.L. Cardoso, and E. S. Muxfeldt Relation of Left Ventricular Hypertrophy With Systemic Inflammation and Endothelial Damage in Resistant Hypertension Hypertension, October 1, 2007; 50(4): 723 - 728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Jorgensen, T. Jenssen, S. H. Johnsen, E. B. Mathiesen, I. Heuch, O. Joakimsen, E. Fosse, and B. K. Jacobsen Albuminuria as risk factor for initiation and progression of carotid atherosclerosis in non-diabetic persons: the Tromso Study Eur. Heart J., February 1, 2007; 28(3): 363 - 369. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Pietroiusti, M. Giuliano, A. Magrini, A. Bergamaschi, and A. Galante Cytotoxin-Associated Gene A Strains of Helicobacter Pylori Represent a Risk Factor for the Development of Microalbuminuria in Type 2 Diabetes. Diabetes Care, June 1, 2006; 29(6): 1399 - 1401. [Full Text] [PDF]
|
|
|
|
|
|
D. Nitsch, D. F. Dietrich, A. von Eckardstein, J.-M. Gaspoz, S. H. Downs, P. Leuenberger, J.-M. Tschopp, O. Brandli, R. Keller, M. W. Gerbase, et al. Prevalence of renal impairment and its association with cardiovascular risk factors in a general population: results of the Swiss SAPALDIA study Nephrol. Dial. Transplant., April 1, 2006; 21(4): 935 - 944. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Khosla and G. Bakris Lessons Learned from Recent Hypertension Trials about Kidney Disease Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 229 - 235. [Full Text] [PDF]
|
|
|
|
|
|
G. Bakris Proteinuria: A Link to Understanding Changes in Vascular Compliance? Hypertension, September 1, 2005; 46(3): 473 - 474. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Arnlov, J. C. Evans, J. B. Meigs, T. J. Wang, C. S. Fox, D. Levy, E. J. Benjamin, R. B. D'Agostino, and R. S. Vasan Low-Grade Albuminuria and Incidence of Cardiovascular Disease Events in Nonhypertensive and Nondiabetic Individuals: The Framingham Heart Study Circulation, August 16, 2005; 112(7): 969 - 975. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Pedrinelli, G. Dell'Omo, V. Di Bello, G. Pellegrini, L. Pucci, S. Del Prato, and G. Penno Low-Grade Inflammation and Microalbuminuria in Hypertension Arterioscler Thromb Vasc Biol, December 1, 2004; 24(12): 2414 - 2419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Bakris, V. Fonseca, R. E. Katholi, J. B. McGill, F. H. Messerli, R. A. Phillips, P. Raskin, J. T. Wright Jr, R. Oakes, M. A. Lukas, et al. Metabolic Effects of Carvedilol vs Metoprolol in Patients With Type 2 Diabetes Mellitus and Hypertension: A Randomized Controlled Trial JAMA, November 10, 2004; 292(18): 2227 - 2236. [Abstract] [Full Text] [PDF]
|
|